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Primary duodenal adenocarcinoma is a rare malignant neoplasm accounting for 
0.3% of all gastrointestinal tract carcinomas. We herein present one case of duode-
nal adenocarcinoma after duodenal neuroendocrine carcinoma. Poorly differenti-
ated duodenal neuroendocrine carcinoma with liver metastasis (TxNxM1) was 
confirmed, and eight cycles of palliative chemotherapy (5-fluorouracil/etoposide/
cisplatin) were administered. The patient was then in a clinically complete re-
sponse status. About 1 year later, newly developed adenocarcinoma was detected at 
the same site. It was completely surgically resected, and the patient was cured.
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INTRODUCTION
The average annual age-adjusted incidence of malig-
nant tumors of the small intestine is 9.9 per million 
people. The incidence is 3.7 per million people for ade-
nocarcinomas, 3.8 for neuroendocrine tumors (NETs), 
1.1 for lymphomas, and 1.3 for sarcomas [1]. Among 
these, adenocarcinoma is the most common malig-
nancy affecting the duodenum, carcinoid is the most 
common tumor in the ileum, and sarcomas and lym-
phomas can develop throughout the entire small bowel 
[2]. In the duodenum, the proportions of adenocarcino-
ma, malignant endocrine tumor, lymphoma, and sar-
coma were 73.8%, 13.7%, 6.3%, and 6.2%, respectively, 
despite the fact that the reported relative incidence var-
ies considerably with the patient population under 
study [3].
The World Health Organization classification cate-
gorizes gastroenteropancreatic NETs into several 
groups: 1) well-differentiated NETs, 2) low-grade ma-
lignant carcinoma, 3) high-grade malignant carcino-
ma, and 4) mixed tumors (adenocarcinoma/neuroen-
docrine carcinoma) [4]. The prognosis of poorly 
differentiated NETs is poor [5]. Its survival time is 
known to be as short as 14.5 months.
Despite this rareness, the patient in this case study 
had serial development of both a NET and adenocarci-
noma in duodenum. Despite the poor prognosis of 
poorly differentiated metastatic NETs, the patient was 
cured by chemotherapy and remained tumor-free.
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CASE REPORT
A 60-year-old male was admitted to the gastrointesti-
nal medical clinic of Severance Hospital to undergo an 
operation for duodenal cancer.
The patient had developed renal tuberculosis 30 
years previously, received medical treatment for several 
months, and was completely cured. In June 2009, he 
visited a local clinic after experiencing general weak-
ness and melena over a period of 1 month, was diag-
nosed with duodenal cancer with multiple liver metas-
tases (Fig. 1A and 1B), and was transferred to our 
hospital.
Esophagogastroduodenoscopy (EGD) (Fig. 1C) con-
firmed an ulcerofungating mass with poorly differen-
tiated neuroendocrine carcinoma at the superior duo-
denal angle of the duodenum (Fig. 2A and 2B). Initial 
computed tomography (CT) showed multiple liver me-
tastases. From November 2009 to January 2010, six cy-
cles of palliative chemotherapy comprising 5-f luoro-
uracil (5-FU) at 1,000 mg/m2 (days 1 to 3), etoposide at 
100 mg/m2 (days 1 to 3), and cisplatin at 70 mg/m2 (day 1) 
were performed. After these treatments, fludeoxyglu-
cose uptake was no longer seen on positron emission 
tomography (PET)-CT. There was no remnant malig-
nant lesion on EGD, and the patient had only patholog-
Figure 1. In June 2009, computed tomography (CT) and esophagogastroduodenoscopy revealed a duodenal tumor with liver 
metastasis. (A) CT findings: homogeneous, poorly enhanced wall thickening of the duodenum and a large, homogeneous, 
poorly enhanced node (2.6 cm) in the triangular area were found. (B) CT findings: innumerable homogeneously enhancing 
metastatic nodules in the liver were detected. (C) Endoscopic finding: ulcerofungating mass at the superior descending angle.
Figure 2. Pathology and immunohistochemistry findings. CD56 was positive (A, immunohistochemistry, × 100; B, H&E, × 
100). The nuclei were vesicular and contained coarsely granular chromatin and prominent nucleoli. The tumor has infiltrated 
the submucosa: poorly differentiated neuroendocrine carcinoma.
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ically confirmed chronic gastritis. Two more cycles of 
chemotherapy were performed. He was subsequently 
confirmed to have no evidence of disease in February 
2010.
In June 2010, a polyp was detected in the former le-
sion site and was confirmed to be chronic inflamma-
tion by EGD biopsy. There were no abnormal findings 
on CT. In February 2011, a polyp was detected by EGD at 
the same site as that of the former polyp (Fig. 3A). This 
was pathologically confirmed to be adenocarcinoma by 
immunohistochemical staining. Chromogranin A and 
synaptophysin, which are neuroendocrine markers, 
were negative. Carcinoembryonic antigen (CEA), which 
is usually detected in cases of adenocarcinoma, was 
positive (Fig. 3B). The patient was admitted for an opera-
tion. Upon examination, his vital signs were normal. 
He reported no symptoms, and there was no palpable 
mass, organs, or tenderness in the abdomen. The re-
sults of a complete blood count were normal, as were the 
plasma levels of routine chemistry and tumor markers 
(CEA and CA 19-9). Magnetic resonance imaging (MRI) 
and PET-CT showed no abnormal findings at the site of 
the duodenal lesion, which was detected by EGD. How-
ever, there were suspicious metastatic lesions at seg-
ments 6/7 and segment 7 of the liver, so intraoperative 
radiofrequency ablation was planned and performed on 
28 February 2011. The duodenal adenocarcinoma was 
not invading the mesentery. Pylorus-preserving pan-
creaticoduodenectomy was performed. A definite lesion 
was not found by intraoperative sonography, but a le-
sion was found attached to the right margin of the right 
hepatic vein on preoperative MRI. Thus, right posterior 
segmental curative resection of the liver was performed.
The surgical pathology results showed moderately 
differentiated duodenal adenocarcinoma at the site of 
the primary lesion, and mild nonspecific reactive hepa-
titis was confirmed in the liver via immunohistochem-
ical staining (Fig. 4). At the site of the primary lesion, 
there were no neuroendocrine cells; only pure adeno-
carcinoma cells were present. Therefore, the final stage 
was T1N0M0, and the patient underwent no further ad-
juvant chemotherapy. The patient is undergoing fol-
low-up in the outpatient department without recur-
rence.
DISCUSSION
Therapeutically, patients with poorly differentiated 
metastatic neuroendocrine cancer are usually advised 
to undergo cytoreductive chemotherapy corresponding 
to the medical treatment of small cell carcinoma of the 
lungs [5,6]. Thus, the patient in this case study under-
went eight cycles of palliative chemotherapy (5-FU/
etoposide/cisplatin) to treat duodenal neuroendocrine 
carcinoma with poorly differentiated TxNxM1. Al-
Figure 3. (A) Endoscopic finding: duodenal polypoid mass at the superior descending angle. (B) Immunohistochemistry find-
ing: carcinoembryonic antigen was positive (immunohistochemistry, × 100).
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though the cure rate is extremely poor, as mentioned 
above, the patient continued to show no evidence of dis-
ease for 1 year.
After 1 year without evidence of disease, moderately 
differentiated duodenal adenocarcinoma was identi-
fied and resected completely. An analysis of 491 cases 
claimed that the optimal treatment of small bowel ade-
nocarcinoma continues to be complete resection, and 
periampullary and most proximal duodenal carcino-
mas require pancreatoduodenectomy for curative re-
section [7]. Therefore, the patient in this case under-
went pylorus-preserving pancreaticoduodenectomy.
Only inflammation was present in the liver patholo-
gy results, and a sufficient resection margin was con-
firmed during pathological examination of the duode-
nal adenocarcinoma with a low TNM stage (pT1N0M0). 
In stage I duodenal adenocarcinoma, which is com-
pletely resected, the median overall survival and 5-year 
overall survival rate are reportedly 136.5 months and 
68.6%, respectively. There are currently no obvious 
benefits of adjuvant chemotherapy in terms of survival 
in early stage duodenal adenocarcinoma [8]. Hence, 
routine check-ups several months apart to monitor for 
recurrence have been adequate in this patient [9].
Figure 4. The tumor cells are arranged in a glandular pattern: adenocarcinoma, moderately differentiated (A, H&E, × 100; B, 
H&E, × 12.5). Immunohistochemistry findings: (C) CD56 was negative; (D) chromogranin A was negative; (E) synaptophysin was 
negative (C, D, E, immunohistochemistry, × 40).
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In conclusion, in the present case duodenal poorly 
differentiated neuroendocrine carcinoma was success-
fully cured with chemotherapy. Moreover, adenocarci-
noma, the pathology of which is totally different, was 
found at the same site and was also cured surgically. 
This is a very rare case of successful management. 
In other respects, it is possible that the duodenal neo-
plasm of this patient had both neuroendocrine and ad-
enocarcinoma components initially. The presence of 
an exocrine component in gastrointestinal neuroendo-
crine neoplasms, especially in high-grade neuroendo-
crine carcinomas, has been widely documented. There-
fore, if we assume that the duodenal neoplasm had a 
small adenocarcinoma component, the duodenal ade-
nocarcinoma discovered later can be explained by the 
idea that the neuroendocrine component had disap-
peared secondary to chemotherapy and that only the 
adenocarcinoma component remained. However, the 
initial pathology assessment utilized only several small 
tissues obtained by EGD forceps. As a result, the pres-
ence and the proportion of the adenocarcinoma com-
ponent in the initial duodenal neoplasm cannot be 
confirmed. Nevertheless, poorly differentiated multi-
ple metastatic neuroendocrine cancers were treated, a 
pathologically complete response was obtained, and 
the remnant adenocarcinoma was resected completely. 
This case is very rare in this respect.
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